



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Donald S. Karanewsky et al.
Application No. : 09/765,105
Filed : January 16, 2001
For : C-TERMINAL MODIFIED OXAMYL DIPEPTIDES AS
INHIBITORS OF THE ICE/CED-3 FAMILY OF
CYSTEINE PROTEASES
Art Unit : 1646
Docket No. : 480140.442C1
Date : August 6, 2001

Box Missing Parts
Commissioner for Patents
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:


In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the 11 references set forth on the attached Forms PTO-1449. This application is a continuation-in-part and relies, under 35 U.S.C. § 120, on the earlier filing date of prior USAN 09/745,204, filed December 19, 2000 and USAN 09/177,549, filed October 22, 1998, now issued as US Patent No. 6,197,750; and claims the benefit of PCT/US 99/15074, filed July 1, 1999 and Provisional Application No. 60/091,689, filed July 2, 1998. The references listed on page 1 of the attached Forms PTO-1449 were submitted to and/or cited by the Patent and Trademark Office in these prior applications and, therefore, are not required to be provided in this application. If the Examiner wishes, copies will be provided upon request. However, reference set forth on page 2 of the attached Forms PTO-1449 has not been previously submitted to and/or cited by the office and is submitted herewith. As to any reference supplied or made of record on the attached Forms PTO-1449, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to

traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method.

Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Respectfully submitted,
Seed Intellectual Property Law Group PLLC



Karl R. Hermanns
Registration No. 33,507

KRH:sfl

Enclosures:

Forms PTO-1449 (2 Sheets)
1 Cited Reference

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031

D:\NrPortbl\iManage\SHANEL\183248_1.DOC

FORM PTO-1449
(REV.7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
480140.442C1APPLICATION NO.
09/765,105
INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)
APPLICANTS
Donald S. Karanewsky et al.FILING DATE
January 16, 2001GROUP ART UNIT
1646**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,869,519	02/09/99	Karanewsky et al.	514	415	
	AB	5,877,197	03/02/99	Karanewsky et al.	514	397	
	AC	5,968,927	10/19/99	Karanewsky et al.	514	214	
	AD						
	AE						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AF	EP 618 223	10/05/94	EPO		
	AG	EP 623 592	11/09/94	EPO		
	AH	WO 97/22619	06/26/97	WIPO		
	AI					
	AJ					

OTHER PRIOR ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

AK	/	Ilugunin et al., "Protease activity of m-vitro transcribed and translated caenorhabditis elegans cell death gene (ced-3) product" J. Biol. Chem., Feb. 16, 1996, 271(7) 3517-12 abstract only, 1996.
AL	/	Juan TS et al., "Molecular characterization of mouse and rat CPP32 beta gene encoding a cysteine protease resembling interleukin-1 beta converting enzyme and CED-3" Oncogene, 13(4)749-55, Aug. 15, 1996 (Abstract only).
AM		Gagliardini et al. Prevention of Vertebrate Neuronal Death by the crmA Gene, Science vol. 263, Feb. 11, 1994 pp. 826-828.
AN		Marx. Cell Death Studies Yield Cancer Clues; Science vol. 259, Feb. 5, 1993, pp. 760-761.
AO		Sleath et al., Substrate Specificity of the Protease that Processes Human Interleukin--1.beta., The Journal of Biological Chemistry, vol. 265, No. 24, pp. 14526-14528, Aug. 25, 1990.

EXAMINER	DATE CONSIDERED
----------	-----------------

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV.7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 480140.442C1	APPLICATION NO. 09/765,105
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		APPLICANTS		Donald S. Karanewsky et al.	
		FILING DATE		GROUP ART UNIT 1646	
		January 16, 2001			

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA	6,197,750 B1	03/06/01	Karanewsky et al.	514	19	
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						
	BH						
	BI						
	BJ						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	BK					
	BL					
	BM					
	BN					
	BO					

OTHER PRIOR ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	BP		
	BQ		
	BR		

EXAMINER	DATE CONSIDERED
----------	-----------------

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).